President had stakes in Regeneron and Gilead, makers of antibody cocktail, Remdesivir

President Donald Trump previously reported he earned capital gains from Regeneron Pharmaceuticals and Gilead Sciences Inc., the manufacturers of two of the medicines he’s taken as part of his COVID-19 treatment plan.

According to a 2017 financial disclosure form filed with the U.S. Office of Government Ethics in June 2017, Trump had a capital gain of $50,001 to $100,000 for Regeneron Pharmaceuticals and $100,001 to $1 million for Gilead Sciences Inc. The form notes the information was of April 15, 2017.

Trump’s subsequent disclosure forms, including his 2020 form signed July 31, did not list Regeneron or Gilead.

Trump received a single 8-gram dose of Regeneron’s polyclonal antibody cocktail as a precautionary measure, according to his physician Sean Conley. The antibody cocktail is in four late-stage clinical trials, and its safety and efficacy have not been fully evaluated by any regulatory authority, the company said on its webpage. As part of Operation Warp Speed, New York state-based Regeneron won a $450 million federal contract in July to manufacture and supply the company’s antibody cocktail REGN-COV2.

The New York Times reported Friday that Regeneron’s chief executive, Dr. Leonard S. Schleifer, a member of Trump’s golf club in Westchester County, New York, said Trump’s medical staff reached out to the company for permission to use the drug and the Food and Drug Administration cleared it. “All we can say is that they asked to be able to use it, and we were happy to oblige,” Schleifer told the Times, calling it a “compassionate use” case. Trump isn’t the first patient to try the experimental treatment outside of the clinical trial through compassion use. “When it’s the president of the United States, of course, that gets – obviously – gets our attention,” Schleifer told the Times. Regeneron stock rose $19.20 a share in after-hours trading.

Trump also is taking Gilead’s remdesivir, which has been authorized for COVID-19 patients by the FDA under an emergency use declaration. Trials showed effectiveness under some circumstances.

Remdesivir received a guarded endorsement in April from Dr. Anthony Fauci, director of the National Institute of Allergy and Infectious Diseases at the National Institutes of Health, when it was announced as a new tool in the fight against the virus at a presidential new conference.